vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and DIODES INC (DIOD). Click either name above to swap in a different company.
DIODES INC is the larger business by last-quarter revenue ($391.6M vs $247.1M, roughly 1.6× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 2.6%, a 8.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 15.4%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $12.4M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 13.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
ANIP vs DIOD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $391.6M |
| Net Profit | $27.5M | $10.2M |
| Gross Margin | — | 31.1% |
| Operating Margin | 14.1% | 3.4% |
| Net Margin | 11.1% | 2.6% |
| Revenue YoY | 29.6% | 15.4% |
| Net Profit YoY | 367.5% | 23.8% |
| EPS (diluted) | $1.14 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $391.6M | ||
| Q3 25 | $227.8M | $392.2M | ||
| Q2 25 | $211.4M | $366.2M | ||
| Q1 25 | $197.1M | $332.1M | ||
| Q4 24 | $190.6M | $339.3M | ||
| Q3 24 | $148.3M | $350.1M | ||
| Q2 24 | $138.0M | $319.8M | ||
| Q1 24 | $137.4M | $302.0M |
| Q4 25 | $27.5M | $10.2M | ||
| Q3 25 | $26.6M | $14.3M | ||
| Q2 25 | $8.5M | $46.1M | ||
| Q1 25 | $15.7M | $-4.4M | ||
| Q4 24 | $-10.3M | $8.2M | ||
| Q3 24 | $-24.2M | $13.7M | ||
| Q2 24 | $-2.3M | $8.0M | ||
| Q1 24 | $18.2M | $14.0M |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 31.5% | ||
| Q1 25 | — | 31.5% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 33.7% | ||
| Q2 24 | — | 33.6% | ||
| Q1 24 | — | 33.0% |
| Q4 25 | 14.1% | 3.4% | ||
| Q3 25 | 15.9% | 3.0% | ||
| Q2 25 | 6.6% | 2.6% | ||
| Q1 25 | 13.3% | 0.4% | ||
| Q4 24 | -2.3% | 3.5% | ||
| Q3 24 | -13.8% | 6.2% | ||
| Q2 24 | 3.7% | 1.2% | ||
| Q1 24 | 14.8% | 4.3% |
| Q4 25 | 11.1% | 2.6% | ||
| Q3 25 | 11.7% | 3.6% | ||
| Q2 25 | 4.0% | 12.6% | ||
| Q1 25 | 8.0% | -1.3% | ||
| Q4 24 | -5.4% | 2.4% | ||
| Q3 24 | -16.3% | 3.9% | ||
| Q2 24 | -1.7% | 2.5% | ||
| Q1 24 | 13.2% | 4.6% |
| Q4 25 | $1.14 | $0.23 | ||
| Q3 25 | $1.13 | $0.31 | ||
| Q2 25 | $0.36 | $0.99 | ||
| Q1 25 | $0.69 | $-0.10 | ||
| Q4 24 | $-0.45 | $0.18 | ||
| Q3 24 | $-1.27 | $0.30 | ||
| Q2 24 | $-0.14 | $0.17 | ||
| Q1 24 | $0.82 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $377.0M |
| Total DebtLower is stronger | — | $25.7M |
| Stockholders' EquityBook value | $540.7M | $1.9B |
| Total Assets | $1.4B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $377.0M | ||
| Q3 25 | $262.6M | $386.4M | ||
| Q2 25 | $217.8M | $327.3M | ||
| Q1 25 | $149.8M | $343.9M | ||
| Q4 24 | $144.9M | $316.1M | ||
| Q3 24 | $145.0M | $319.3M | ||
| Q2 24 | $240.1M | $273.9M | ||
| Q1 24 | $228.6M | $276.0M |
| Q4 25 | — | $25.7M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | — | $26.4M | ||
| Q1 25 | — | $20.5M | ||
| Q4 24 | — | $20.7M | ||
| Q3 24 | — | $22.2M | ||
| Q2 24 | — | $20.3M | ||
| Q1 24 | — | $20.9M |
| Q4 25 | $540.7M | $1.9B | ||
| Q3 25 | $505.8M | $1.9B | ||
| Q2 25 | $436.8M | $1.9B | ||
| Q1 25 | $418.6M | $1.8B | ||
| Q4 24 | $403.7M | $1.8B | ||
| Q3 24 | $405.9M | $1.8B | ||
| Q2 24 | $455.8M | $1.8B | ||
| Q1 24 | $452.0M | $1.7B |
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.4B | $2.5B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $920.8M | $2.4B | ||
| Q1 24 | $914.5M | $2.4B |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $38.1M |
| Free Cash FlowOCF − Capex | $29.1M | $12.4M |
| FCF MarginFCF / Revenue | 11.8% | 3.2% |
| Capex IntensityCapex / Revenue | 0.5% | 6.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 3.74× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $137.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $38.1M | ||
| Q3 25 | $44.1M | $79.1M | ||
| Q2 25 | $75.8M | $41.5M | ||
| Q1 25 | $35.0M | $56.7M | ||
| Q4 24 | $15.9M | $81.8M | ||
| Q3 24 | $12.5M | $54.4M | ||
| Q2 24 | $17.4M | $14.4M | ||
| Q1 24 | $18.3M | $-31.1M |
| Q4 25 | $29.1M | $12.4M | ||
| Q3 25 | $38.0M | $62.8M | ||
| Q2 25 | $71.8M | $21.1M | ||
| Q1 25 | $32.5M | $40.8M | ||
| Q4 24 | $13.5M | $62.1M | ||
| Q3 24 | $7.7M | $39.4M | ||
| Q2 24 | $13.0M | $-3.5M | ||
| Q1 24 | $13.7M | $-51.5M |
| Q4 25 | 11.8% | 3.2% | ||
| Q3 25 | 16.7% | 16.0% | ||
| Q2 25 | 34.0% | 5.8% | ||
| Q1 25 | 16.5% | 12.3% | ||
| Q4 24 | 7.1% | 18.3% | ||
| Q3 24 | 5.2% | 11.2% | ||
| Q2 24 | 9.4% | -1.1% | ||
| Q1 24 | 10.0% | -17.1% |
| Q4 25 | 0.5% | 6.6% | ||
| Q3 25 | 2.7% | 4.2% | ||
| Q2 25 | 1.9% | 5.6% | ||
| Q1 25 | 1.3% | 4.8% | ||
| Q4 24 | 1.3% | 5.8% | ||
| Q3 24 | 3.2% | 4.3% | ||
| Q2 24 | 3.2% | 5.6% | ||
| Q1 24 | 3.3% | 6.7% |
| Q4 25 | 1.10× | 3.74× | ||
| Q3 25 | 1.66× | 5.54× | ||
| Q2 25 | 8.87× | 0.90× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 9.93× | ||
| Q3 24 | — | 3.95× | ||
| Q2 24 | — | 1.80× | ||
| Q1 24 | 1.00× | -2.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
